NYB (NYB Holdings) ROC %: -1,728.68% (As of Sep. 2025)


What is NYB Holdings ROC %?

NYB Holdings NYB ROC % is -1,728.68% as of Sep. 2025.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. NYB Holdings's annualized return on capital (ROC %) for the quarter that ended in Sep. 2025 was -1,728.68%.

As of today (2026-06-25), NYB Holdings's WACC % is 0.00%. NYB Holdings's ROC % is 0.00% (calculated using TTM income statement data). NYB Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.

NYB Holdings  (NAS:NYB) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, NYB Holdings's WACC % is 0.00%. NYB Holdings's ROC % is 0.00% (calculated using TTM income statement data). NYB Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

NYB Holdings ROC % Related Terms

NYB Holdings ROC % Historical Data

* Premium members only.

The historical data trend for NYB Holdings's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NYB Holdings ROC % Chart

NYB Holdings Annual Data
Trend Sep24 Sep25
ROC %
-117,366.67 -1,728.68

NYB Holdings Semi-Annual Data
Sep24 Sep25
ROC % -117,366.67 -1,728.68

NYB Holdings ROC % Calculation

NYB Holdings's annualized Return on Capital (ROC %) for the fiscal year that ended in Sep. 2025 is calculated as:

ROC % (A: Sep. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Sep. 2024 ) + Invested Capital (A: Sep. 2025 ))/ count )
=-3.345 * ( 1 - 0% )/( (0.0029999999999992 + 0.384)/ 2 )
=-3.345/0.1935
=-1,728.68 %

where

Invested Capital(A: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.305 - 5.214 - ( 0.285 - max(0, 5.217 - 0.305+0.285))
=0.0029999999999992

Invested Capital(A: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1.265 - 0.19 - ( 0.889 - max(0, 0.255 - 0.946+0.889))
=0.384

NYB Holdings's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2025 is calculated as:

ROC % (Q: Sep. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Sep. 2025 ))/ count )
=-3.345 * ( 1 - 0% )/( (0.0029999999999992 + 0.384)/ 2 )
=-3.345/0.1935
=-1,728.68 %

where

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.305 - 5.214 - ( 0.285 - max(0, 5.217 - 0.305+0.285))
=0.0029999999999992

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1.265 - 0.19 - ( 0.889 - max(0, 0.255 - 0.946+0.889))
=0.384

Note: The Operating Income data used here is one times the annual (Sep. 2025) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -1,728.68% mean?
NYB Holdings (NYB) has a ROC % of -1,728.68% as of Sep. 2025. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on NYB Holdings and its competitors.
Is NYB Holdings' ROC % too high?
NYB Holdings' current ROC % is -1,728.68%.
How does NYB Holdings' ROC % compare to ?
NYB Holdings' ROC % of -1,728.68% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on NYB Holdings and its competitors. NYB Holdings's current ROC % is -1,728.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NYB Holdings stock overvalued right now?
NYB Holdings (NYB) has a current ROC % of -1,728.68%. The current ROC % is -1,728.68%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For NYB Holdings (NYB), the current ROC % is -1,728.68% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NYB Holdings Business Description

Comparable Companies
Address 456 Alexandra Road, No. 04-07, Fragrance Empire Building, Singapore, SGP, 119962
NYB Holdings Ltd, along with its subsidiaries, is a pre-clinical biopharmaceutical company engaged in the research and development of therapeutics and nutraceuticals derived from biodiversity, including tropical medicinal plants with a history of traditional use. It focuses on discovering and developing natural compounds for applications in oncology and other chronic diseases, and also offers a consumer nutraceutical product line.